Trial Profile
Multicenter, randomized, double-blind, placebo controlled, crossover single dose study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, effect on gastric emptying of TZP-101 IV infusion in diabetic gastroparesis patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2009
Price :
$35
*
At a glance
- Drugs Ulimorelin (Primary) ; Ghrelin agonists
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Adverse reactions; Pharmacokinetics
- 04 Apr 2008 New trial record.